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Abstract
Background: Cardiovascular anomalies are the largest group of congenital anomalies and the major cause of death
in young children, with various data linking rising atrial septal defect incidence (ASDI) with prenatal cannabis
exposure. Objectives / Hypotheses. Is cannabis associated with ASDI in USA? Is this relationship causal?
Methods: Geospatiotemporal cohort study, 1991–2016. Census populations of adults, babies, congenital anomalies,
income and ethnicity. Drug exposure data on cigarettes, alcohol abuse, past month cannabis use, analgesia abuse
and cocaine taken from National Survey of Drug Use and Health (78.9% response rate). Cannabinoid concentrations
from Drug Enforcement Agency. Inverse probability weighted (ipw) regressions. Analysis conducted in R.
Results: ASDI rose nationally three-fold from 27.4 to 82.8 / 10,000 births 1991–2014 during a period when tobacco
and alcohol abuse were falling but cannabis was rising. States including Nevada, Kentucky, Mississippi and
Tennessee had steeply rising epidemics (Time: Status β-estimate = 10.72 (95%C.I. 8.39–13.05), P < 2.0 × 10 − 16). ASDI
was positively related to exposure to cannabis and most cannabinoids.
Drug exposure data was near-complete from 2006 thus restricting spatial modelling from 2006 to 2014, N = 282. In
geospatial regression models cannabis: alcohol abuse term was significant (β-estimate = 19.44 (9.11, 29.77), P = 2.2 ×
10 − 4); no ethnic or income factors survived model reduction. Cannabis legalization was associated with a higher
ASDI (Time: Status β-estimate = 0.03 (0.01, 0.05), P = 1.1 × 10 -3). Weighted panel regression interactive terms
including cannabis significant (from β-estimate = 1418, (1080.6, 1755.4), P = 7.3 × 10 -15). Robust generalized linear
models utilizing inverse probability weighting interactive terms including cannabis appear (from β-estimate = 78.88,
(64.38, 93.38), P = 1.1 × 10 -8). Marginal structural models with machine-aided SuperLearning association of ASDI with
high v. low cannabis exposure R.R. = 1.32 (1.28, 1.36). Model e-values mostly > 1.5.
(Continued on next page)
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Conclusions: ASDI is associated with cannabis use, frequency, intensity and legalization in a spatiotemporally
significant manner, robust to socioeconomicodemographic adjustment and fulfilled causal criteria, consistent with
multiple biological mechanisms and similar reports from Hawaii, Colorado, Canada and Australia. Not only are these
results of concern in themselves, but they further imply that our list of the congenital teratology of cannabis is as
yet incomplete, and highlight in particular cardiovascular toxicology of prenatal cannabinoid and drug exposure.
Keywords: Atrial septal defect, Cannabis, Cannabinoid, Δ9-tetrahydrocannabinol, Cannabigerol, Cannabidiol,
Mechanisms, Congenital anomalies, Cardiac malformations

Introduction
Atrial Septal Defect (secundum type) (ASD) is one of
the commonest of the cardiovascular congenital anomalies which are themselves the commonest form of congenital defect. Congenital defects are the commonest
cause of mortality in children under the age of 5 years
[1]. The Centres for Disease Control Atlanta, Georgia,
(CDC) publishes rates of congenital anomalies across the
USA annually based on reports from state-based registries through the National Births Defects Prevention
Network which CDC sponsor. Review of these data indicate that in recent years ASD appears to be increasing in
some US States for reasons which were not apparent.
Previous reports from Hawaii and Colorado had linked
ASD with cannabis exposure [2, 3]. Indeed the report on
Colorado showed that ASD incidence (ASDI) followed a
sigmoidal trajectory and closely tracked the decade of
cannabis legalization there [3]. Canada Health recently
issued a major report of that nation’s teratological experience which noted a rise in total cardiovascular defects in the northern territories of Canada [4, 5] which
are known to consume more cannabis [6]. Since ASD is
one of the most common cardiovascular defects it is
likely that ASD was represented in this general increase.
Government reports from Australia similarly link high
ASDI with areas of high cannabis use [7]. Moreover 34
congenital defects including nine cardiovascular defects
were recently noted to be more common in the highest
quintile of cannabis using states in the USA than in the
remainder of the country [8].
A previous joint position statement from the American
Academy of Pediatric and the American Heart Association linked prenatal cannabis exposure with ventricular
septal defect and Ebsteins anomaly [9]. The American
College of Obstetricians and Gynaecologists and the Society of Obstetricians and Gynecologists of Canada recommend that women avoid the use of cannabis during
pregnancy [10, 11]. However a detailed investigation of
the association and its potentially causal relationship has
not been reported.
The current study explored three nested hypotheses
which were conceived before beginning the study.
Firstly, was there indeed an increase in ASDI? Secondly,

was the association robust to adjustment for definable
sociodemographic, socioeconomic and drug exposure
covariates across space and time? And thirdly, was the
relationship causal? We were particularly interested to
apply the powerful methods of formal geotemporospatial
analysis and causal inference to these problems. If these
hypotheses were confirmed this would raise the intriguing possibility that, notwithstanding statements from
official authorities, our list of cannabis-associated birth
anomalies remains incomplete, and there is more to
learn in this important area.

Methods
Design

This study was a retrospective observational geotemporospatial epidemiological study of publicly available datasets looking at the relationships of ASD with drug
exposure, ethnicity and socioeconomic data in USA
1989–2016. This study was performed in January 2020.
Data

Data on birth defects was sourced from the National
Birth Defect Prevention Network (NBDPN) annual reports 1988–1989 to 2012–2016 [12]. This report compiles the reports of the State Birth Defects registries in
multi-year groups. The reference year for each report
was the middle year of each report. Data on drug use
was accessed from the National Survey of Drug Use and
Health (NSDUH) conducted annually by the Substance
Abuse and Mental Health Services Administration
(SAMHSA) [13]. This is a nationally representative sample of the non-institutionalized US population. Data on
five drugs was extracted at state level: last month:
cigarette, alcohol abuse or dependence, and cannabis
use; and last year: analgesic abuse and cocaine use. Data
on cannabis use rates by ethnicity was also extracted at
the national level. Data on cannabinoid concentration is
the average concentration of the various cannabinoids
found annually in Drug Enforcement Agency seizures
[14, 15]. Data for the ethnic population of each state was
sourced from the US Census Bureau’s decennial and 5
year annual community surveys via the tidycensus package in “R”.
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Derived variables

Frequency of cannabis use in the last month by ethnicity
was sourced from the Substance Abuse and Mental
Health Data Archive and used to calculate a mean number of days used at the Federal level for each year [16].
These measures were multiplied by the last month cannabis use for that state and then by the mean annual
concentration of Δ9-tetrahydrocannabinol (THC) to derive an index of annual ethnic THC exposure at state
level (AETES) referred to in the Tables as an ethnic
“score”. This variable was used to standardize population
ethnicity compositions for known different use rates and
intensity of cannabis use.
Statistics

This analysis was conducted in January 2020 using “R”
Studio version 1.2.5042 based on “R” version 4.0.0 obtained from CRAN [17]. Variables were log-transformed
guided by the Shapiro test. Data was matched and formatted using “R” package dplyr [18], maps and graphs
were drawn in ggplot2 [18, 19] and sf [20], linear regression was performed in base, geofacetting was done in
geofacet, panel regression was done in plm [21], geospatial linkages and weights were assigned in spdep [22],

Page 3 of 12

and Alaska and Hawaii were elided using albersusa and
sp. Factor analysis was done with factoextra. Two-stage
regression including instrumental variables (as indicated)
was conducted in panel and geospatial regression. Model
reduction was by the classical method of serial deletion
of the least significant term. For non-spatial models
missing data was casewise deleted. Missing data was imputed for spatial analysis by temporal kriging (mean substitution) as indicated. Spatial regression was performed
in splm::spreml using a full model with Kapoor, Kelejian,
and Prucha -type spatial errors, spatial lagging, random
errors and serially autocorrelated errors (sem2srre + lag)
in all cases [22–26]. Geospatial models were compared
using the spatial Hausman test.
To balance confounding for measured covariates inverse
probability weights over time (iptw) were computed for
the kriged longitudinal data in a time-based paradigm
(from package ipw [27]) and added to the dataset. Robust
inferential analysis was conducted with iptw using mixed
effects models (nlme), panel models (plm [21]) and generalized linear models (survey [28]). Marginal structural
models were performed in doubly robust targeted minimum loss-based estimation (drtmle) which includes
augmented-iptw. Adaptive machine learning was also

A

B

C

D

Fig. 1 Univariate ASD trends. a ASDI over time. b ASDI by state THC exposure. c ASDI by THC exposure dichotomized into high and low ASDI
states. d Cluster Analysis of the ASD – Cannabis exposure data
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conducted using drtmle to access SuperLearner libraries
which heightened inferential power. Generalized linear
models was used to specify model structure and machine
learning was used to increase inferential sensitivity. eValues were computed (EValue [29–31]) to assess the required impact of unmeasured confounding. P < 0.05 was
considered significant.
Data availability statement

Data including software programming in R has been made
publicly available through the Mendeley data repository at
URL: https://doi.org/10.17632/vrnfbytrrr.1.
Ethics

The study was approved by the Human Ethics Research
Committee of the University of Western Australia April
1st 2019, No. RA/4/20/4724.

Results
Across the NBDPN annual reports 1988–1989 to 2012–
2016 (referred to as reference years 1989–2014) there
were 347 reports of rates of atrial septal defect

Fig. 2 ASDI by (a) Drugs and (b) Cannabinoids by US State
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(secundum type). Across the period 2002–2016 the
NSDUH was completed by 952,717 respondents out of
1,207,606 selected for the survey, a mean response rate
of 78.89%. The survey quotes a mean weighted interview
response rate of 74.1%.
The data for the 37 states contributing data are shown
in eTable 1 and map-graphically in eFigure 1.
Figure 1a shows the time course of ASD across the
USA and notes a rising trend. The mean rate in 1991
was 27.4/10,000 births and 82.4/10,000 in 2014, a 3.02fold rise. Figure 1b plots the ASD Rate against the product of the last month cannabis use rate and the THC potency, and importantly, also shows an apparently rising
trend with cannabis exposure. Close inspection of Fig. 1b
shows that it seems to be bimodal with both upper and
lower zones. When the highest ASD states from the
2012–2016 period, Nevada, Alaska, Mississippi, Tennessee, Ohio, Oregon and Kentucky are grouped together
the appearance found in Fig. 1c is derived. eTable 2
quantitates these changes by linear regression and notes
highly significant changes with time (β-estimate = 2.52,
(95%C.I. 1.56, 3.48); with THC exposure index (β-
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estimate = 24.93, (1.06, 45.8)) and between the high and
average ASD-rate states (Exposure: Status interaction (βestimate = 10.72 (8.39–13.05), P < 2.2 × 10− 16). Figure 1d
shows that formal cluster analysis correctly dissects out
these zones. The reason for this bimodality is unclear,
but may relate to local cannabinoid concentrations or
intensity of use.
eFigure 2A shows the ASDI by cannabis consumption
quintiles. An abrupt jump is noted between quintiles 3
and 4 shown as non-overlapping notches on the boxplots (ChiSq. for trend = 8147.9, df = 4, P < 10− 300). This
is highlighted in eFig. 2B which dichotomizes the data
around this point (Students-t = 3.48, df = 40.07, P =
0.0012). Ranges are provided in eTable 3 (Quintiles 1–3
45.46 (24.50, 93.30) (median, interquartile range) and
Quintiles 4–5 94.70 (35.35, 175.20)).
eFigure 3 is a geofacetted plot of the ASDI by state
across the USA with each state in approximately is actual position. Strongly rising trends are noted in Nevada,
Kentucky, Tennessee, Mississippi, Missouri, Colorado
and Alaska. eFigure 4 is a similar geofacetted plot of the
ASDI this time against the THC exposure index. Curiously strongly rising trends are noted in states including
Nevada, Kentucky, Mississippi and Tennessee.
Figure 2a shows the relationship of the ASDI to the
drug exposure level in each state. Falling ASDI are noted
with alcohol abuse, binge alcohol, cocaine and alcohol or
drug abuse categories. Figure 2b is a similar illustration
of the relationship of ASD to various cannabinoids but
here one notes a rising relationship with most cannabinoids with the notable exception of cannabidiol.
eFigure 5A displays the rate of cannabinoid exposure
by year and notes that for cannabidiol this has been a
negative trend which makes interpretation of its relationship with ASD complex (Fig. 2b). Figure 5B is an

A

B

Fig. 3 ASDI by legal status of cannabis. a Raw data plot. b log(ASDI) plot

annual plot of the ASD: cannabidiol relationship and
notes a more positive relationship in 2006 and 2007 at a
time when cannabidiol exposure levels were higher.
eFigure 6 charts the ASDI by the ethnic composition.
Whilst the relationship is negative in the AfricanAmerican community it appears to be positive amongst
American Indians / Alaskan Natives (AIAN). As shown
in eTable 4 these differences are significant.
When the ASDI is charted against the ethnic exposure
to THC (AETES) as in eFigure 7, these ethnic differences disappear as uniform rising trends are seen.
As noted in eFigure 8 there is a non-significant relationship of ASDI with median household income.
These data may be regressed in their totality by panel
regression which is a technique well suited to serial geospatial panel data with missing values. The results shown
in eTable 5 are notable in that when median household
income and racial composition are regressed by themselves they are not significant. When drugs, income and
ethnicity are regressed together ethnicity and income remain in the final model but have negative β-coefficients,
and terms including cannabis also remain in the final
model (from β-estimate = 22.25 (10.13, 150.24), P = 3.8 ×
10− 4).
When one charts the impact of the legal status of cannabis on the ASDI the data shown in Fig. 3 is obtained
for the (A) raw and (B) log-transformed data respectively. As shown in eTable 6 the time:legal status interaction is highly significant (β-estimate = 0.03 (0.012,
0.48), P = 0.0011) for legal cannabis compared to other
categories.
Missing data are not permitted in geospatial analytical
techniques. Temporal kriging is an accepted method of
completing such values. eTable 7 shows all the data with
kriged values coloured. From 2006 when all the drug
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Table 1 Geotemporospatial Regression
Instrumental ± Lagged
Variables

Parameters & Values
Parameter

Model
β-Coefficient (95%C.I.)

P-value

LogLik

Parameters

Value

P-Value

Drugs
0 Lags
spreml(ASD_Rate ~ cigmon * mrjmon * abodalc + anlyr + cocyr)
Δ9THC_Exposure

mrjmon

phi

2.57E-05

1

Cannabigerol_Exposure

cocyr

−0.25 (− 0.43, − 0.07)

0.0085

psi

0.9629

<2e-16

cigmon: mrjmon

−0.87 (−1.71, − 0.03)

0.0416

rho

− 0.0414

0.7944

lambda

−0.0455

0.7702

phi

2.57E-05

1

0.49 (0.16, 0.82)

0.0033

−56.071

Drugs & 4 Races
0 Lags
Δ9THC_Exposure

spreml(ASD_Rate ~ cigmon * mrjmon * abodalc + anlyr + cocyr + 4_Races)

Cannabigerol_Exposure

mrjmon

0.49 (0.16, 0.82)

0.0033

−56.071

Caucasian_Daily_Score

cocyr

−0.25 (−0.43, − 0.07)

0.0085

psi

0.9629

<2e-16

African.Am_Daily_Score

cigmon: mrjmon

−0.87 (−1.71, − 0.03)

0.0416

rho

− 0.0414

0.7944

lambda

−0.0455

0.7702

phi

15.4679

7.26E-07

Asian.Am_Daily_Score
AIAN_Daily_Score
Drugs
2 Lags
spreml(ASD_Rate ~ cigmon * mrjmon * abodalc + anlyr + cocyr)
Δ9THC_Exposure, 0:2

mrjmon

0.46 (0.07, 0.85)

0.0237

− 73.445

Cannabigerol_Exposure, 0:2

psi

0.6471

0.0002

rho

−0.0352

0.8684

lambda

−0.0667

0.7517

Drugs
4 Lags
spreml(ASD_Rate ~ cigmon * mrjmon * abodalc + anlyr + cocyr)
Δ9THC_Exposure, 0:4

mrjmon: abodalc

Cannabigerol_Exposure, 0:4

cigmon: mrjmon: abodalc

19.44 (9.11, 29.77)
−45.14 (− 75.09, − 15.19)

0.0002
0.0031

−55.133

phi

1.3947

NA

psi

0.9530

<2e-16

rho

0.0204

0.9361

lambda

−0.1420

0.5256

Abbreviations
4_Races Caucasian-American, African-American, Hispanic-American, Asian-American
AIAN American Indian / Alaska Native
Technical Notes:
phi Idiosyncratic component of the spatial error term
psi Individual time-invariant component of the spatial error term
rho Spatial autoregressive parameter
lambda Spatial autocorrelation coefficient

data is available there are 267 ASD datapoints. 29
(eTable 8) have been inserted by kriging bringing the
total (eTable 9) to 296 points. The complete spatial dataset is map-graphed in eFigure 9.
The spatial links used to derive the spatial weights are
shown in eFigure 10 (A) in edited and (B) in final format
after conceptually eliding (moving) Alaska and Hawaii
into relationship with California.
The outcomes of spatial regression are shown in Table 1.
Median household income and demographics was not

significant either with or without instrumental variables either alone or in combination (not shown). When the drugs
alone were regressed the results shown in the upper part of
the table were derived. When drugs and race and a
full complement of instrumental variables was
regressed the same model was returned with terms
including cannabis continuing to be significant. When
a drug-only model was regressed at 2 years lag the
results shown were derived. When the procedure was
repeated at 4 years of lag to account for the moving

Reece and Hulse BMC Pediatrics

(2020) 20:539

average style of data published by NBDPN the results
were again as shown. In each model terms including
cannabis remain significant in final models.
Models were compared. Based on their logLik
values the first and fourth models are best. When
these are directly compared spatial Hausman tests
(ChiSq. = 11.18, df = 1, P = 8.25 × 10− 4) indicate the superiority of the drug model lagged to 4 years. One
notes that in this model terms including cannabis
were significant from (β-estimate = 19.44 (9.11, 29.77),
P = 2.2 × 10− 4).
The kriged dataset may also be used to derive inverse
probability weights (iptw). These are applied to panel
models in eTable 10 with a marked gain in both power
(F = 15.62 on df = 7280 to F = 1062.95, df = 13,274) and
inferential sensitivity with interactive terms including
cannabis significant (from β-estimate = 1418, (1080.6,
1755.4), P = 7.3 × 10− 15).
iptw can be applied to mixed models (eTable 11)
where interactive terms including cannabis are significant (from β-estimate = 6.80, (5.86, 7.74), P < 10− 4).
iptw can be utilized in robust conditional generalized
linear models (glm). Table 2 sets out these results in an
additive model, and in interactive models with a fourway interaction in drug terms, a four-way interaction in
ethnic cannabis exposure index, and an additive combination of two three way interactions between drugs and
ethnic cannabis exposure. Highly significant interactive
terms including cannabis appear (from β-estimate =
78.88, (64.38, 93.38), P = 1.1 × 10− 8).
iptw can also be used in glm in drtmle models to formulate marginal structural models with both glm and
adaptive machine learning algorithms using the above
noted increment from the third to the fourth cannabis
exposure quintile as a switch to signal high v. low dose
cannabis exposure (Table 3).
The top line shows that in a SuperLearner model cannabis exposure is significant alone with high v low exposure (0.08, (0.04, 0.13)).
Remaining models include all the covariates shown in
the first column. Models become progressively more
complex moving down the table. The most refined
model is the final one which shows a marginal association of ASDI with high v. low cannabis exposure of
0.93 (0.92, 0.94) v. 0.70 (0.68, 0.72), a relative risk of 1.32
(1.28, 1.36), Wald Z = 18.52, P = 1.3 × 10− 76).
Sensitivity analyses may be conducted for these results
using the eValue which quantitates the association an
unobserved variable would have to have with both the
measured parameter and the outcome to obviate the results. eTable 12 presents a variety of analyses with many
results significantly divergent from unity making uncontrolled confounding unlikely across all major models and
all major findings.
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Discussion
This is the first study to our knowledge to use geotemporospatial and formal inferential analysis to assess the
association between cannabis use and ASDI. Data confirm a positive relationship between cannabis use and
ASDI. Specifically, we firstly confirmed that ASDI increased three-fold 1989–2016. Notably this ASDI elevation is largely accounted for by states such as Nevada,
Kentucky, Mississippi and Tennessee and associated
with the legalization of cannabis. Second, increases in
ASDI occurred over a period when alcohol, tobacco and
cocaine use were falling, which implicates rising cannabis exposure [32]. Cannabis legalization was associated
with higher ASDI.
In multivariable geotemporospatial regression the
cannabinoid-ASDI link was confirmed across space and
time together and was robust to adjustment for other socioeconomic and ethnodemographic variables.
Formal investigation of the cannabinoid-ASDI link by
the tools of causal inference including by inverse probability time-based weighting in robust generalized linear
models, doubly robust augmented inverse probability
weighting and machine SuperLearning techniques confirmed the link and confirmed its robustness to adjustment for other measured variables in pseudorandomized
populations. Sensitivity analysis utilizing evalues confirmed that unmeasured variables were unlikely to account for the size of the effect observed.
This combination of geotemporal analysis, the iptw inferential analysis and the sensitivity analysis in the context of the preliminary concordant trends together make
a powerful combined epidemiological argument for a
causal relationship between cannabinoid exposure and
ASDI.
Hence this study made affirmative findings in relation
to all three opening hypotheses. ASDI is indeed rising;
drug and cannabinoid exposure account for this in a
manner robust to adjustment for the usual socioeconomicodemographic covariates in final geospatial models;
and finally the cannabinoid-ASDI relationship fulfills criteria for causality.
The association of cannabis use with atrial septal defect was first described in a report from Hawaii where
its use in isolation was noted to be linked to an increase
in ASDI of 6.12-fold (95%C.I. 1.98–14.35) [2]. It is interesting that many of these findings were also recently observed in Colorado [3]. The pronounced increase in
ASDI across the decade of cannabis legalization there
was noted above. Similar findings were also seen in relation to cannabidiol.
One important issue to consider is the existence of
biological pathways from cannabis exposure to cardiovascular embryogenesis. Embryologically the heart forms
from a complex series of sources including the primary
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Table 2 Robust General Linear Model with Inverse Probability Weights
Parameter

β-Coefficient (95%C.I.)

P-value

0.73 (0.46, 1)

2.8E-05

Additive Model
AIAN.Amn
NHCauc.Amn_Cannabis

5.42 (2.42, 8.42)

0.0015

Analgesics

0.72 (0.21, 1.23)

0.0100

Asian_Cannabis

1 (0.24, 1.76)

0.0160

NHAfrc.Amn_Cannabis

−4.55 (−7.53, −1.57)

0.0060

Alcohol

−34.96 (−49.93, − 19.99)

0.0001

NHPI_Cannabis

− 0.3 (− 0.42, − 0.18)

9.0E-05

Cauc.Amn

− 2.89 (− 3.91, − 1.87)

8.9E-06

Hispanic_Cannabis

− 1.18 (− 1.59, − 0.77)

5.6E-06

Afrc.Amn

− 0.82 (− 1.09, − 0.55)

4.4E-06

Cannabis

913.3 (597.54, 1229.06)

5.8E-05

Analgesics

842 (549.57, 1134.43)

6.1E-05

Cannabis: Analgesics

294.1 (188.73, 399.47)

8.3E-05

Cigarettes: Alcohol

114,400 (68,496.8, 160,303.2)

0.0002

NHCauc.Amn_Cannabis

5.68 (3.37, 7.99)

0.0003

Cigarettes: Alcohol: Cannabis

40,180 (23,672.88, 56,687.12)

0.0003

Cigarettes: Alcohol: Analgesics

36,720 (21,412.4, 52,027.6)

0.0003

Interactive Models
Four-Way Interaction Amongst Drugs: Tobacco * Alcohol * Cannabis * Analgesics

Cigarettes: Alcohol: Cannabis: Analgesics

12,870 (7331.04, 18,408.96)

0.0005

Afrc.Amn

−0.47 (−0.88, −0.06)

0.0440

Cauc.Amn

−3.03 (−4.95, −1.11)

0.0080

NHPI_Cannabis

−0.28 (− 0.44, − 0.12)

0.0027

Hispanic_Cannabis

− 1.99 (− 3.01, − 0.97)

0.0020

Alcohol: Cannabis: Analgesics

− 3184 (− 4540.71, − 1827.29)

0.0004

Alcohol: Analgesics

− 9055 (− 12,759.4, − 5350.6)

0.0003

NHAfrc.Amn_Cannabis

−2.38 (− 3.36, − 1.4)

0.0003

Alcohol: Cannabis

− 9987 (− 14,012.84, − 5961.16)

0.0003

Alcohol

− 28,390 (− 39,456.16, − 17,323.84)

0.0002

Cigarettes: Cannabis: Analgesics

− 1191 (− 1619.85, − 762.15)

8.6E-05

Cigarettes: Analgesics

− 3418 (− 4618.11, − 2217.89)

6.8E-05

Cigarettes: Cannabis

− 3686 (− 4975.29, − 2396.71)

6.5E-05

Cigarettes

−10,550 (− 14,176, − 6924)

5.5E-05

Four-Way Interaction Amongst Ethnic_Cannabis: Cauc.Amn * Afrc.Amn * Asian.Amn * AIAN.Amn
Asian_Cannabis

78.88 (64.38, 93.38)

1.1E-08

NHCauc.Amn_Cannabis: Asian_Cannabis

294.32 (235.62, 353.02)

3.5E-08

NHCauc.Amn_Cannabis

549.56 (436.25, 662.87)

5.5E-08

NHCauc.Amn_Cannabis: Asian_Cannabis: AIAN.Amn_Cannabis

51.74 (40.9, 62.58)

6.9E-08

NHAfrc.Amn_Cannabis: AIAN.Amn_Cannabis

51.34 (34.03, 68.65)

2.6E-05

Cigarettes

9.15 (5.41, 12.89)

0.0002

NHCauc.Amn_Cannabis: NHAfrc.Amn_Cannabis: Asian_Cannabis

6.72 (2.33, 11.11)

0.0084

Cocaine

−1.23 (−1.99, −0.47)

0.0060

Afrc.Amn

−0.59 (− 0.84, − 0.34)

0.0004
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Table 2 Robust General Linear Model with Inverse Probability Weights (Continued)
β-Coefficient (95%C.I.)

P-value

Alcohol

−31.75 (−45.31, − 18.19)

0.0003

Cauc.Amn

−2.69 (−3.65, − 1.73)

4.5E-05

Parameter

AIAN.Amn_Cannabis

−122.94 (− 162.47, − 83.41)

1.6E-05

NHCauc.Amn_Cannabis: NHAfrc.Amn_Cannabis

−67.25 (−88.59, − 45.91)

1.3E-05

Asian_Cannabis: AIAN.Amn_Cannabis

−66.75 (− 85.02, − 48.48)

2.3E-06

NHAfrc.Amn_Cannabis: Asian_Cannabis: AIAN.Amn_Cannabis

−50.24 (−63.74, − 36.74)

1.8E-06

Hispanic_Cannabis

− 11.55 (− 14.35, − 8.75)

4.8E-07

NHAfrc.Amn_Cannabis: Asian_Cannabis

− 195.38 (− 233.99, − 156.77)

3.1E-08

NHAfrc.Amn_Cannabis

− 426.55 (− 505.56, − 347.54)

1.3E-08

NHCauc.Amn_Cannabis: NHAfrc.Amn_Cannabis: AIAN.Amn_Cannabis

−9.25 (− 10.96, −7.54)

1.2E-08

3 + 3 Way Interactions: Tobacco * Alcohol * Cannabis + Cauc.Amn * AIAN.Amn * Asian.Amn
Cigarettes: Alcohol

3696.88 (2707.37, 4686.39)

1.5E-07

Analgesics

1.53 (1.1, 1.96)

4.3E-07

Cigarettes: Alcohol: Cannabis

1467.06 (997.23, 1936.89)

2.5E-06

Cannabis

28.63 (18.07, 39.19)

1.9E-05

AIAN.Amn

0.71 (0.44, 0.98)

5.0E-05

Cauc.Amn

−2.52 (−4.24, −0.8)

0.0083

Afrc.Amn

− 0.78 (−1.09, − 0.47)

4.0E-05

Alcohol: Cannabis

−368.51 (− 503.71, − 233.31)

1.8E-05

Cigarettes: Cannabis

−113.89 (− 151.25, −76.53)

3.6E-06

Cigarettes

− 288.27 (− 376.25, − 200.29)

1.2E-06

Alcohol

− 950.06 (− 1226.77, − 673.35)

5.8E-07

and secondary heart fields, the proepicardium and migration of cells from the neural crest [33]. Many molecular cascades are involved including retinoic acid, the
core regulatory network of MEF2, NKX2, GATA, Tbx,
and Hand and various micro-RNA’s, and later TGFβ,
BMP’s and notch become key molecular organizers.
Genetic defects of Nkx 2–5, GATA4, Tbx5 and Downs
syndrome are known to be linked with ASD pathogenesis [33].
Cannabinoid type 1 receptors (CB1R) are found in the
embryo from the twelfth week of foetal life and exist in
high density on the endocardial cushion material [34–
37]. It has been noted that cannabinoids can act on the
cardiovasculature via at least seven different receptors including the type 1 and 2 cannabinoid receptors, vanilloid
receptors, GPR55, PPAR, abnormal cannabidiol receptors
and others [38]. On occasion cannabinoids are known to
induce proinflammatory states including arteritis and
angiopathies [36, 37, 39–42]. Moreover in all seven studies
to have examined the issue cannabis has been linked with
gastroschisis which is believed to have a largely vasculopathic origin due to the implication of several vasoactive
drugs, with a secondary defect in the right side of the abdominal wall arising due interference with the vascular
supply. Hence there would appear to be a number of

biological pathways potentially linking prenatal cannabis
exposure with downstream adverse embryological cardiovascular outcomes.
This notable convergence of evidence linking cannabis
exposure in USA, Colorado, Hawaii, Canada and Australia
with biologically plausible pathways implies that our usual
list of cannabis-related birth defects is as yet incomplete
[2–4, 7]. Such an acknowledgement also raises the question of how many other birth defects are attributable to
currently unidentified environmental causes.
The dramatic and recent rises in ASDI in some
states is of particular concern. We feel that one possible explanation for the apparently bimodal response to THC exposure in the high ASD states may
be an increase in the intensity of use or rising local
cannabinoid potency, which is apparently not being
well detected in NSDUH, which does not reveal publicly near daily cannabis consumption on a state
basis. It is possible that changed agricultural arrangements in states previously majoring in tobacco
cultivation with crop diversification into hemp products may explain some of the effects in Midwestern
states. That this metric is apparently not being
picked up in NSUDH is a matter for further
investigation.
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Table 3 Doubly Robust Targeted Minimum Loss-Based Estimation Using Generalized Linear Models and SuperLearner Adaptive
Machine Learning
Covariates

Model

Lower
Exposure

Higher
Exposure

R.R.

Difference w
Higher Exposure

Wald
Test, Z

P-Value

Cannabis_Monthly

Initial drtmle mrjmon
SuperLearner Model

0.68 (0.61, 0.69)

0.76 (0.72, 0.80)

1.11 (1.05, 1.18)

0.08 (0.04, 0.13)

3.53

0.0004

Cigarettes

Binomial glm

0.68 (0.66, 0.69)

0.86 (0.84, 0.87)

1.26 (1.23, 1.29)

0.18 (0.16, 0.20)

17.16

5.02E-66

SuperLearner

0.71 (0.69, 0.73)

0.98 (0.97, 0.98)

1.37 (1.34, 1.40)

0.27 (0.24, 0.29)

20.08

1.15E-89

0.68 (0.66, 0.70)

0.86 (0.84, 0.87)

1.26 (1.22, 1.30)

0.17 (0.16, 0.20)

17.16

5.03E-66

0.68 (0.66, 0.70)

0.82 (0.81, 0.84)

1.21 (1.18, 1.25)

0.14 (0.12, 0.16)

13.16

1.57E-39

0.68 (0.66, 0.70)

0.78 (0.75, 0.82)

1.15 (0.10, 1.20)

0.10 (0.7, 0.14)

5.95

2.62E-09

0.68 (0.67, 0.70)

0.75 (0.71, 0.78)

1.08 (1.06, 1.11)

0.06 (0.02, 0.10)

2.85

0.0043

0.68 (0.66, 0.70)

0.79 (0.75, 0.83)

1.16 (1.9, 1.24)

0.11 (0.06, 0.16)

4.72

7.74E-06

0.70 (0.68, 0.72)

0.93 (0.92, 0.94)

1.32 (1.28, 1.36)

0.23 (0.21, 0.25)

18.52

1.32E-76

Alcohol_Abuse
Cannabis_Monthly
Analgesic_Abuse
Cocaine_Annual

Mixed SuperLearner Glm Model Series

% White
% African-American

No Interactions

% Asian

- Additive

% American Indian / Alaskan Natives
NHWhite_Daily_Cannabis_
Use x THC_Concentration

One Interaction

NHBlack_Daily_Cannabis_
Use x THC_Concentration

- Tobacco x Cannabis

NHAsian_Daily_Cannabis_
Use x THC_Concentration
NHAIAN_Daily_Cannabis_
Use x THC_Concentration

Three Interactions

NHHispanic_Daily_Cannabis_
Use x THC_Concentration

- Tobacco * Cannabis *
Alcohol

Median_Household_Income
Four Substance Interactions
- Tobacco * Cannabis *
Alcohol * Analgesics
Three Ethnic Interactions
NHWhite_Daily_Cannabis_
Use x THC_Concentration *
NHAsian_Daily_Cannabis_
Use x THC_Concentration *
NHAIAN_Daily_Cannabis_
Use x THC_Concentration
Three Substance x Three
Ethnic Interactions
- Tobacco * Cannabis *
Alcohol *
NHWhite_Daily_Cannabis_
Use x THC_Concentration *
NHAsian_Daily_Cannabis_
Use x THC_Concentration *
NHAIAN_Daily_Cannabis_
Use x THC_Concentration

Study strengths include the use of US national census
and American Community Survey, and nationally representative drug use surveys. One of the great advantages
of conducting the present analysis on USA data is that it
represents the most comprehensive data set globally.
Secondly, this study represents the first use of formal
geotemporospatial and causal inferential analytical

techniques to assess the cannabis-ASD relationship.
Thirdly, results are consistent with other reports and research from a range of jurisdictions which have used different methodologies and likely have had a range of
different and likely potential confounders. Study limitations are firstly, data employed ecological aggregate-level
data, which do not related to any specific individual; that
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is although we can say that State increased level of cannabis use correlated with same State increased rates of
congenital anomalies we cannot specifically attribute a
case of ASD to prenatal cannabis exposure from parents
shown to be using high level cannabis. High intensity
use of cannabis at state level is also not captured in the
publicly available NSDUH data. Moreover congenital
anomaly data from certain high cannabis use states including Washington, Oregon, Vermont and Maine are
incomplete in many years which would weaken our estimates downwards. Secondly, utilised drug use data relied
on self-report, the accuracy of which is difficult to validate. Thirdly, although we attempted to adjust for socioeconomic variables including tobacco, alcohol, and
cocaine that may be routinely used by consumers of cannabis, it is not possible to completely remove confounding from observational data.
The replication of major findings in several geographically independent locations globally [2–4, 7, 9, 43, 44]
suggest that the findings are widely generalizable. There
are now well established biological mechanisms by
which cannabis might increase the likelihood of ASD.
Collectively therefore these diverse and converging sets
of information support the results of the geotemporal
and causal inferential analyses.
It is appears that the medical, political and broader
community are yet to fully comprehend or appreciate
the higher rate of birth defects associated with cannabis
legalization. The present report indicates this remains an
open question which warrants further vigorous research
and careful investigation, for example at higher geospatial resolution and using patient-matched data and validated biomarker approaches [45] and at the molecular,
cellular and epigenetic levels.

Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s12887-020-02431-z.
Additional file 1: eTable 1. ASD Rate Data. eTable 2. ASD Rate –
Linear Regressions. eTable 3. ASD Rate by Cannabis Use Quintile
Groupings. eTable 4. Impact of Ethnicity over time on ASD Rate.
eTable 5. Panel Regression Raw Dataset. eTable 6. Impact of Cannabis
Legal Paradigm on ASD Rate. eTable 7. Kriged Data Input. eTable 8.
Inserted Data for Kriging. eTable 9. Kriged Data Input for Geospatial and
IPW Analysis. eTable 10. Unweighted and Weighted Panel Regressions
on Kriged Data. eTable 11. Mixed Effects Model with Inverse Probability
Weighting. eTable 12. eValue Sensitivity Analysis.
Additional file 2: eFigure 1. Map-graph of log (ASDI) by state over
time. This graph is original.
Additional file 3: eFigure 2. ASDI by (A) quintiles and (B) by quintiles
dichotomized as quintiles 1, 2 and 3 v. quintiles 4 and 5.
Additional file 4: eFigure 3. Geofacetted plot with each US state in
approximately their appropriate position, showing the ASDI over time for
each state.
Additional file 5: eFigure 4. Geofacetted plot with each US state in
approximately their appropriate position, showing the ASDI over a

Page 11 of 12

denominator of the product of state level cannabis use by national THC
concentration (which thus provides an estimate of the state level THC
exposure).
Additional file 6: eFigure 5. Concentration of cannabinoids by state
across time. National averaged trend line is shown in each case. (A)
Selected cannabinoids with loess (localized polynomial) fitted curves. (B)
Linear regression lines for state level cannabidiol exposure.
Additional file 7: eFigure 6. ASD rate by ethnicity by state.
Additional file 8: eFigure 7. ASD rate by ethnicity collated for the
whole nation (A) by individual ethnicity and (B) for all ethnicities pooled.
Additional file 9: eFigure 8. ASD rate as a function of the median
household income.
Additional file 10: eFigure 9. Map-graphs depicting the log (ASDI) by
state by year for the temporally kriged dataset. These maps are originals.
Additional file 11: eFigure 10. Geospatial links (A) edited and (B) final
used in geospatiotemporal modelling. These maps are originals.

Abbreviations
AIAN: American Indian / Alaska Native; AETES: Annual Ethnic THC Exposure at
State Level; Amn: American; ASD: Atrial septal defect (secundum type);
ASDI: Atrial septal defect incidence; BMP: Bone morphogenetic protein;
CRAN: Comprehensive “R” Archive Network; GATA: GATA Binding Protein 1;
GPR55: G-Protein Receptor 55; Hand: Heart and Neural Crest Derivatives
Expressed Proteins; lambda: Spatial autocorrelation coefficient;
MEF2: Myocyte Enhancer Factor 2; NBDPN: National Birth Defects Prevention
Network; NH: Non-Hispanic; NHPI: Non-Hispanic Pacific Islander; NKX2: NK2
Homeobox-1; NSDUH: National Survey of Drug Use and Health;
phi: Idiosyncratic component of the spatial error term; PPAR: Peroxisome
Proliferator-Activator Receptor; psi: Individual time-invariant component of
the spatial error term; 4_Races: Caucasian-American, African-American,
Hispanic-American, Asian-American; rho: Spatial autoregressive parameter;
SAMHSA: Substance Abuse and Mental Health Services Administration;
Tbx: T-Box transcription factor; TGFβ: Transforming Growth Factor-β; THC: Δ9Tetrahydrocannabinol
Acknowledgements
Not applicable.
Authors’ contributions
ASR assembled the data, designed and conducted the analyses, and wrote
the first manuscript draft. GKH provided technical and logistic support, cowrote the paper, assisted with gaining ethical approval, provided advice on
manuscript preparation and general guidance to study conduct. All authors
have read and approved the manuscript.
Funding
No funding was provided for this study. No funding organization played any
role in the design and conduct of the study; collection, management,
analysis, and interpretation of the data; preparation, review, or approval of
the manuscript; and decision to submit the manuscript for publication.
Availability of data and materials
All data generated or analysed during this study are included in this
published article and its supplementary information files. Data has been
made publicly available on the Mendeley Database Repository and can be
accessed from this URL https://doi.org/10.17632/p7myt3fbzs.1
Ethics approval and consent to participate
The Human Research Ethics Committee of the University of Western
Australia provided ethical approval for the study to be undertaken 7th June
2019 (No. RA/4/20/4724). Consent to participate was not required as the
data utilized was derived from publicly available anonymous datasets and no
individual identifiable data was utilized.
Consent for publication
Not applicable.

Reece and Hulse BMC Pediatrics

(2020) 20:539

Competing interests
The authors declare that they have no competing interests.
Received: 1 July 2020 Accepted: 17 November 2020

References
1. Congenital Heart Defects (CHDs) https://www.cdc.gov/ncbddd/
heartdefects/data.html. Accessed 20 Apr 2020.
2. Forrester MB, Merz RD. Risk of selected birth defects with prenatal illicit
drug use, Hawaii, 1986-2002. J Toxicol Environ Health. 2007;70(1):7–18.
3. Reece AS, Hulse GK. Cannabis Teratology Explains Current Patterns of
Coloradan Congenital Defects: The Contribution of Increased Cannabinoid
Exposure to Rising Teratological Trends. Clinical Pediatrics. 2019;58(10):1085–123.
4. Public Health Agency of Canada: Congenital Anomalies in Canada, 2013. A
perinatal health surveillance report in. Edited by Public Health Agency of
Canada HC, vol. 1. Ottawa: Health Canada; 2013: 1–115.
5. Reece A. S., Hulse G.K.: Canadian Cannabis Consumption and Patterns of
Congenital Anomalies: An Ecological Geospatial Analysis. J Addiction Med
2020, In Press.
6. National Cannabis Survey, Second Quarter, 2018 https://www.facebook.
com/StatisticsCanada/posts/1636405843137586:0. Accessed 20 Apr 2020.
7. Queensland Maternal and Perinatal Quality Council 2017: Queensland
mothers and babies 2014 and 2015. In. Edited by Health Q, vol. 1. Brisbane:
Queensland Health; 2018: 1–70.
8. Reece A.S., Hulse G.K.: Cannabis in pregnancy – rejoinder, Exposition and
Cautionary Tales Psychiatric Times. 2020-37. https://www.psychiatrictimes.
com/view/cannabis-pregnancy-rejoinder-exposition-cautionary-tales.
Accessed 12 Oct 2020.
9. Jenkins KJ, Correa A, Feinstein JA, Botto L, Britt AE, Daniels SR, Elixson M,
Warnes CA, Webb CL. American Heart Association Council on cardiovascular
disease in the Y: noninherited risk factors and congenital cardiovascular
defects: current knowledge: a scientific statement from the American Heart
Association Council on cardiovascular disease in the young: endorsed by
the American Academy of Pediatrics. Circulation. 2007;115(23):2995–3014.
10. Ordean A, Wong S, Graves L. No. 349-substance use in pregnancy. J Obstet
Gynaecol Can. 2017;39(10):922–37 e922.
11. Braillon A, Bewley S. Committee Opinion No. 722: Marijuana Use During
Pregnancy and Lactation. Obstet Gynecol. 2018;131(1):164.
12. National Birth Defects Prevention Network https://www.nbdpn.org/ar.php.
Accessed 20 Dec 2019.
13. National Survey of Drug Use and Health 2018, NSDUH https://www.samhsa.
gov/data/all-reports. Accessed 20 Dec 2019.
14. ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes
in Cannabis potency over the last 2 decades (1995-2014): analysis of current
data in the United States. Biol Psychiatry. 2016;79(7):613–9.
15. ElSohly MA, Ross SA, Mehmedic Z, Arafat R, Yi B, Banahan BF 3rd. Potency
trends of delta9-THC and other cannabinoids in confiscated marijuana from
1980-1997. J Forensic Sci. 2000;45(1):24–30.
16. Substance Abuse and Mental Health Data Archive (SAMHDA) https://www.
datafiles.samhsa.gov/. Accessed 20 Dec 2019.
17. R: A Language and Environment for Statistical Computing https://www.Rproject.org/.
18. Wickham H, Averick M, Bryan J, Chang W, McGowan LD, Francios R,
Groelmund G, Hayes A, Henry L, Hester J, et al. Welcome to the Tidyverse.
Journal of Open Source Software. 2019;4(43):1686–91.
19. Wickham H. ggplot2: elegant graphics for data analysis. New York: SpringerVerlag; 2016.
20. Pebesma E. Simple features for R: standardized support for spatial vector
data. The R Journal. 2018;10(1):439–46.
21. Package 'plm' https://cran.r-project.org/web/packages/plm/plm.pdf.
Accessed 20 Dec 2019.
22. Bivand R., Anselin L., Berke O., Bernat A., Carvalho M., Chun Y., Dormann C.,
Dray S., Halbersma R., Lewis-Koh N. et al: The spdep package. In: CRAN;
2007: 1–143.
23. Millo G. Maximum likelihood estimation of spatially and serially correlated
panels with random effects. Computational Statistics Data Analysis. 2014;71:
914–33.
24. Millo G., Piras G.: Package 'splm'. In.: CRAN; 2018: 1–27.
25. Croissant Y, Millo G. Panel data econometrics with R, vol. 1. Oxford: John
Wiley and Sons; 2019.

Page 12 of 12

26. Millo G, Piras G. Splm: spatial panel data models in R. J Stastistical Software.
2012;47(1):1–38.
27. Van der Wal WM, Geskus RB. ipw: an R package for inverse Probabilty
weighting. J Stat Softw. 2011;43(13):1–23.
28. Lumley T.: Complex Surveys: a guide to analysis using R, vol. 1: Wiley; 2010.
29. Package 'EValue' https://cran.r-project.org/web/packages/EValue/EValue.pdf.
Accessed 20 Dec 2019.
30. VanderWeele TJ, Ding P. Sensitivity analysis in observational research:
introducing the E-value. Ann Intern Med. 2017;167(4):268–74.
31. VanderWeele TJ, Ding P, Mathur M. Technical considerations in the use of
the E-value. J Causal Inference. 2019;7(2):1–11.
32. McCantz-Katz E: 2017 Annual report snippets, NSDUH, SAMHSA, USA DHHS
- selected streamlined trends. In. Edited by Substance Abuse and Mental
Health Services Administration US Department of Health and Human
Services, vol. 1. Rockville, Maryland: SAMHSA, DHHS, USA; 2018: 1–78.
33. Carlson BM. Human embryology and developmental biology, vol. 1.
Philadelphia: Elsevier; 2014.
34. Bukiya AN, Jackson S, Sullivan R, Tate D, Moore B, Mari G, Dopico AM,
Schlabritz-Loutsevitch N. Regulation of fetal cerebral arterial diameter by
ethanol and endocannabinoids (eCBs) in a baboon model. Regulation of
fetal cerebral arterial diameter by ethanol and endocannabinoids (eCBs) in a
baboon model. Alcohol Clin Exp Res. 2014;38(Suppl. 1):31A.
35. Kuntamallappanavar G, Jackson S, Tate D, Sullivan R, Schlabritz-Lutsevich N,
Mari G, Dopico A, Bukiya A. Role of the endocannabinoid system in alcohol
action on fetal cerebral artery diameter. Alcoholism: Clinical and
Experimental Research Conference. 2015;39(Suppl. 1):222A.
36. Pacher P, Steffens S, Hasko G, Schindler TH, Kunos G. Cardiovascular effects
of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.
Nat Rev Cardiol. 2018;15(3):151–66.
37. Vidinsky B, Gal P, Pilatova M, Vidova Z, Solar P, Varinska L, Ivanova L, Mojzis
J. Anti-proliferative and anti-angiogenic effects of CB2R agonist (JWH-133) in
non-small lung cancer cells (A549) and human umbilical vein endothelial
cells: an in vitro investigation. Folia Biol (Praha). 2012;58(2):75–80.
38. Cutando L, Maldonado R, Ozaita A. Microglial Activation and Cannabis
Exposure. In: Preedy V, editor. Handbook of Cannabis and Related
Pathologies: Biology, Pharmacology, Diagnosis and Treatment. Volume 1.
New York: Academic Press; 2017. p. 401–12.
39. Seleverstov O, Tobiasz A, Jackson JS, Sullivan R, Ma D, Sullivan JP, Davison S,
Akkhawattanangkul Y, Tate DL, Costello T, et al. Maternal alcohol exposure
during mid-pregnancy dilates fetal cerebral arteries via endocannabinoid
receptors. Alcohol. 2017;61:51–61.
40. Yamaji K, Sarker KP, Kawahara K, Iino S, Yamakuchi M, Abeyama K,
Hashiguchi T, Maruyama I. Anandamide induces apoptosis in human
endothelial cells: its regulation system and clinical implications. Thromb
Haemost. 2003;89(5):875–84.
41. Molica F, Burger F, Thomas A, Staub C, Tailleux A, Staels B, Pelli G, Zimmer
A, Cravatt B, Matter CM, et al. Endogenous cannabinoid receptor CB1
activation promotes vascular smooth-muscle cell proliferation and
neointima formation. J Lipid Res. 2013;54(5):1360–8.
42. Slavic S, Lauer D, Sommerfeld M, Kemnitz UR, Grzesiak A, Trappiel M, ThoneReineke C, Baulmann J, Paulis L, Kappert K, et al. Cannabinoid receptor 1
inhibition improves cardiac function and remodelling after myocardial
infarction and in experimental metabolic syndrome. J Mol Med (Berl). 2013;
91(7):811–23.
43. Reece AS, Hulse GK. Canadian Cannabis consumption and patterns of
congenital anomalies: an ecological geospatial analysis. J Addict Med. 2020;
14(5):e195–210.
44. Wilson PD, Loffredo CA, Correa-Villasenor A, Ferencz C. Attributable fraction
for cardiac malformations. Am J Epidemiol. 1998;148(5):414–23.
45. Reece AS, Wang W, Hulse GK. Pathways from epigenomics and
glycobiology towards novel biomarkers of addiction and its radical cure.
Med Hypotheses. 2018;116:10–21.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.

